- Home
- SBH vs GYRE Comparison
SBH vs GYRE Comparison
Compare SBH & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBH
- GYRE
- Stock Information
- Founded
- SBH 1964
- GYRE 2002
- Country
- SBH United States
- GYRE United States
- Employees
- SBH N/A
- GYRE N/A
- Industry
- SBH Other Specialty Stores
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SBH Consumer Discretionary
- GYRE Health Care
- Exchange
- SBH Nasdaq
- GYRE Nasdaq
- Market Cap
- SBH 937.3M
- GYRE 897.1M
- IPO Year
- SBH 2006
- GYRE N/A
- Fundamental
- Price
- SBH $8.81
- GYRE $7.68
- Analyst Decision
- SBH Buy
- GYRE
- Analyst Count
- SBH 6
- GYRE 0
- Target Price
- SBH $12.70
- GYRE N/A
- AVG Volume (30 Days)
- SBH 1.9M
- GYRE 355.4K
- Earning Date
- SBH 05-12-2025
- GYRE 05-09-2025
- Dividend Yield
- SBH N/A
- GYRE N/A
- EPS Growth
- SBH 18.05
- GYRE N/A
- EPS
- SBH 1.76
- GYRE 0.02
- Revenue
- SBH $3,698,409,000.00
- GYRE $100,643,000.00
- Revenue This Year
- SBH $0.46
- GYRE $22.01
- Revenue Next Year
- SBH $1.18
- GYRE $88.14
- P/E Ratio
- SBH $5.04
- GYRE $102.14
- Revenue Growth
- SBH 0.17
- GYRE N/A
- 52 Week Low
- SBH $7.54
- GYRE $6.11
- 52 Week High
- SBH $14.79
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- SBH 51.42
- GYRE 39.36
- Support Level
- SBH $8.66
- GYRE $9.26
- Resistance Level
- SBH $9.03
- GYRE $11.61
- Average True Range (ATR)
- SBH 0.36
- GYRE 1.11
- MACD
- SBH -0.03
- GYRE -0.32
- Stochastic Oscillator
- SBH 20.95
- GYRE 2.38
About SBH Sally Beauty Holdings Inc. (Name to be changed from Sally Holdings Inc.)
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.